For AEterna Zentaris And Keryx (NASDAQ: KERX), Phase 3 Set For Success; Takeover Likely

Keryx Biopharmaceuticals (NASDAQ: KERX) is an emerging small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex), under Special Protocol Assessment (SPA) agreements with the FDA. KERX is Aeterna Zentaris ’ partner and licensee for perifosine in the USA, Canada and Mexico. On Tuesday, Seeking Alpha contributor Jeremy Richards of Private Wealth Fund wrote: “Without question, our company believes strongly in AEterna Zentaris’ (AEZS) lead drug candidate and the likelihood of a takeover of the company.” Richards summarized some of his previous points and provided additional, new analysis of the clinical data to support his position. About Perifosine Richards wrote: “The P3 Perifosine, in combination with Xeloda (Capecitabine) X-Pect study of Keryx, is a trial for a drug combination used to treat metastatic colorectal cancer (mCRC). The combination is referred to as PCAP for Perifosine-Capacitabine. This is a very important study because the number of deaths occurring each year as estimated by WHO is 610,000 worldwide, including 142,570 new cases and 51,370 deaths in the U.S. in 2010. The death rate from mCRC is about 17 per 100,000 people annually in the U.S. CRC is the second most common cancer after lung cancer and more lives are lost each year to colorectal cancer than to breast cancer and AIDS combined. More than 60% of cancers are detected in their late stages. Preliminary evidence is that PCAP is the most effective drug combination known for mCRC.” Read the full article on Seeking Alpha.

Read this article:
For AEterna Zentaris And Keryx (NASDAQ: KERX), Phase 3 Set For Success; Takeover Likely

Tags: , , , , , , , ,

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.